(ALGS) Aligos Therapeutics - Ratings and Ratios
Viral, Liver, Therapies, Small, Molecule, Modulators, siRNA
ALGS EPS (Earnings per Share)
ALGS Revenue
Description: ALGS Aligos Therapeutics
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is pioneering the development of novel therapeutics to tackle unmet medical needs in viral and liver diseases, with a robust pipeline of drug candidates in various stages of clinical trials.
The companys lead drug candidate, ALG-055009, is a small molecule THR-ß agonist that has entered Phase 2a clinical trials for the treatment of non-alcoholic steatohepatitis (NASH), a condition with a growing demand for effective treatments. Additionally, Aligos is advancing ALG-000184, a capsid assembly modulator that has completed Phase 1b clinical trials for the treatment of chronic hepatitis B (CHB), and ALG-125755, a siRNA drug candidate in Phase I clinical trials for CHB treatment.
Aligos is also making strides in developing treatments for coronavirus with ALG-097558, which is currently in Phase 2 clinical trials. The companys partnerships with renowned institutions, such as Merck, Emory University, Luxna Biotech Co., Ltd., and Katholieke Universiteit Leuven, underscore its commitment to leveraging cutting-edge research and technology to drive innovation.
Analyzing the
Based on the available data, a forecast for ALGS can be constructed. Given the current price and SMA trends, a potential short-term target could be $7.00, representing a 15% increase from the current price. However, the long-term downtrend and high volatility suggest that investors should exercise caution. If the companys pipeline continues to progress and partnerships yield positive results, a potential long-term target could be $20.00, representing a 230% increase from the current price. Nevertheless, the negative fundamental data and high volatility make this a high-risk investment.
ALGS Stock Overview
| Market Cap in USD | 74m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2020-10-16 |
ALGS Stock Ratings
| Growth Rating | -68.5% |
| Fundamental | 34.2% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -45.9% |
| Analyst Rating | 4.67 of 5 |
ALGS Dividends
Currently no dividends paidALGS Growth Ratios
| Growth Correlation 3m | 69.3% |
| Growth Correlation 12m | -36.2% |
| Growth Correlation 5y | -91.1% |
| CAGR 5y | -31.39% |
| CAGR/Max DD 3y | -0.34 |
| CAGR/Mean DD 3y | -0.49 |
| Sharpe Ratio 12m | -0.03 |
| Alpha | 0.07 |
| Beta | 0.910 |
| Volatility | 88.10% |
| Current Volume | 39.3k |
| Average Volume 20d | 62k |
| Stop Loss | 8.5 (-7.8%) |
| Signal | -1.04 |
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income (-74.2m TTM) > 0 and > 6% of Revenue (6% = 190.4k TTM) |
| FCFTA -0.60 (>2.0%) and ΔFCFTA 12.58pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 3393 % (prev 954.0%; Δ 2439 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.56 (>3.0%) and CFO -74.9m <= Net Income -74.2m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 6.31 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (10.4m) change vs 12m ago 234.7% (target <= -2.0% for YES) |
| Gross Margin 70.70% (prev 65.61%; Δ 5.09pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 2.61% (prev 7.32%; Δ -4.72pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' -32.10
| (A) 0.80 = (Total Current Assets 127.9m - Total Current Liabilities 20.3m) / Total Assets 134.7m |
| (B) -4.39 = Retained Earnings (Balance) -590.8m / Total Assets 134.7m |
| warn (B) unusual magnitude: -4.39 — check mapping/units |
| (C) -0.62 = EBIT TTM -75.6m / Avg Total Assets 121.8m |
| (D) -17.98 = Book Value of Equity -590.4m / Total Liabilities 32.8m |
| Total Rating: -32.10 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 34.23
| 1. Piotroski 1.0pt = -4.0 |
| 2. FCF Yield data missing |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.16 = 2.49 |
| 5. Debt/Ebitda -0.22 = -2.50 |
| 6. ROIC - WACC data missing |
| 7. RoE -123.9% = -2.50 |
| 8. Rev. Trend -85.24% = -6.39 |
| 9. EPS Trend -57.31% = -2.87 |
What is the price of ALGS shares?
Over the past week, the price has changed by -13.91%, over one month by +5.13%, over three months by +22.44% and over the past year by -35.93%.
Is Aligos Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ALGS is around 6.47 USD . This means that ALGS is currently overvalued and has a potential downside of -29.83%.
Is ALGS a buy, sell or hold?
- Strong Buy: 2
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ALGS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 80.3 | 770.4% |
| Analysts Target Price | 80.3 | 770.4% |
| ValueRay Target Price | 7.3 | -21.1% |
Last update: 2025-09-04 04:31
ALGS Fundamental Data Overview
CCE Cash And Equivalents = 123.1m USD (Cash And Short Term Investments, last quarter)
P/S = 23.2588
P/B = 0.7199
Beta = 2.775
Revenue TTM = 3.17m USD
EBIT TTM = -75.6m USD
EBITDA TTM = -73.5m USD
Long Term Debt = 12.6m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 3.54m USD (from shortTermDebt, last quarter)
Debt = 16.1m USD (Calculated: Short Term 3.54m + Long Term 12.6m)
Net Debt = -11.9m USD (from netDebt column, last quarter)
Enterprise Value = -33.1m USD (73.8m + Debt 16.1m - CCE 123.1m)
Interest Coverage Ratio = unknown (Ebit TTM -75.6m / Interest Expense TTM 0.0)
FCF Yield = -244.2% (FCF TTM -80.9m / Enterprise Value -33.1m)
FCF Margin = -2548 % (FCF TTM -80.9m / Revenue TTM 3.17m)
Net Margin = -2337 % (Net Income TTM -74.2m / Revenue TTM 3.17m)
Gross Margin = 70.70% ((Revenue TTM 3.17m - Cost of Revenue TTM 930.0k) / Revenue TTM)
Tobins Q-Ratio = 0.06 (Enterprise Value -33.1m / Book Value Of Equity -590.4m)
Interest Expense / Debt = 79.39% (Interest Expense 12.8m / Debt 16.1m)
Taxrate = 21.0% (US default)
NOPAT = -75.6m (EBIT -75.6m, no tax applied on loss)
Current Ratio = 6.31 (Total Current Assets 127.9m / Total Current Liabilities 20.3m)
Debt / Equity = 0.16 (Debt 16.1m / last Quarter total Stockholder Equity 101.9m)
Debt / EBITDA = -0.22 (Net Debt -11.9m / EBITDA -73.5m)
Debt / FCF = -0.20 (Debt 16.1m / FCF TTM -80.9m)
Total Stockholder Equity = 59.9m (last 4 quarters mean)
RoA = -55.07% (Net Income -74.2m, Total Assets 134.7m )
RoE = -123.9% (Net Income TTM -74.2m / Total Stockholder Equity 59.9m)
RoCE = -104.4% (set to none) (Ebit -75.6m / (Equity 59.9m + L.T.Debt 12.6m))
RoIC = -126.3% (set to none) (NOPAT -75.6m / Invested Capital 59.9m)
WACC = unknown (E(73.8m)/V(89.9m) * Re(9.36%)) + (D(16.1m)/V(89.9m) * Rd(none%) * (1-Tc(0.21)))
Shares Correlation 3-Years: -25.95 | Cagr: -12.10%
Discount Rate = 9.36% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -80.9m)
EPS Correlation: -57.31 | EPS CAGR: -3.21% | SUE: -0.38 | # QB: 0
Revenue Correlation: -85.24 | Revenue CAGR: -40.94% | SUE: N/A | # QB: None
Additional Sources for ALGS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle